Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Altamira Therapeutics Ltd. EARS
$3.05
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
4214036.00000000
-
week52high
6.60
-
week52low
0.73
-
Revenue
-
P/E TTM
-
Beta
1.40478700
-
EPS
-1.48200000
-
Last Dividend
0.00000000
-
Next Earnings Date
07 мая 2023 г. в 01:13
Описание компании
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Buy | 25 ноя 2020 г. | |
| Needham | Buy | 25 ноя 2020 г. | |
| Leerink Swann | Outperform | 25 ноя 2020 г. | |
| Jefferies | Buy | Buy | 25 ноя 2020 г. |
| Roth Capital | Buy | 13 апр 2017 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии